Intracerebral LV gene therapy ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 20 | Adrenoleukodystrophy | 1 |
20. Adrenoleukodystrophy
Clinical trials : 61 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03727555 (ClinicalTrials.gov) | October 30, 2018 | 25/9/2018 | Lentiviral Gene Therapy for X-ALD | Lentiviral Gene Therapy for X-linked Adrenoleukodystrophy (X-ALD) | X-linked Adrenoleukodystrophy | Genetic: Intracerebral LV gene therapy | Shenzhen Geno-Immune Medical Institute | NULL | Recruiting | N/A | N/A | All | 10 | N/A | China |